[go: up one dir, main page]

WO2002056908A3 - Cellules de presentation d'antigene - Google Patents

Cellules de presentation d'antigene Download PDF

Info

Publication number
WO2002056908A3
WO2002056908A3 PCT/US2002/001318 US0201318W WO02056908A3 WO 2002056908 A3 WO2002056908 A3 WO 2002056908A3 US 0201318 W US0201318 W US 0201318W WO 02056908 A3 WO02056908 A3 WO 02056908A3
Authority
WO
WIPO (PCT)
Prior art keywords
artificial antigen
soluble mhc
presenting cells
presenting cell
mhc molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/001318
Other languages
English (en)
Other versions
WO2002056908A2 (fr
Inventor
William H Hildebrand
Heather D Hickman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/974,366 external-priority patent/US7541429B2/en
Priority claimed from US10/022,066 external-priority patent/US20030166057A1/en
Application filed by Individual filed Critical Individual
Priority to AU2002236777A priority Critical patent/AU2002236777A1/en
Publication of WO2002056908A2 publication Critical patent/WO2002056908A2/fr
Publication of WO2002056908A3 publication Critical patent/WO2002056908A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur une cellule de présentation d'antigène artificielle comprenant un liposome contenant au moins un complexe MHC soluble recombiné-peptide. Ladite cellule peut également contenir au moins une molécule-signal supplémentaire permettant d'influer sur l'intensité et sur la qualité de la réponse immunitaire. La molécule de MHC soluble recombiné est obtenue selon une méthode fondée sur l'amplification par PCR d'ADNg ou d'ADNc, et une marque est fixée à la molécule afin d'ancrer cette dernière au liposome.
PCT/US2002/001318 2001-01-16 2002-01-16 Cellules de presentation d'antigene Ceased WO2002056908A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002236777A AU2002236777A1 (en) 2001-01-16 2002-01-16 Artificial antigen-presenting cells

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26197801P 2001-01-16 2001-01-16
US60/261,978 2001-01-16
US27460501P 2001-03-09 2001-03-09
US60/274,605 2001-03-09
US09/974,366 2001-10-10
US09/974,366 US7541429B2 (en) 2000-10-10 2001-10-10 Comparative ligand mapping from MHC positive cells
US10/022,066 2001-12-18
US10/022,066 US20030166057A1 (en) 1999-12-17 2001-12-18 Method and apparatus for the production of soluble MHC antigens and uses thereof

Publications (2)

Publication Number Publication Date
WO2002056908A2 WO2002056908A2 (fr) 2002-07-25
WO2002056908A3 true WO2002056908A3 (fr) 2003-02-27

Family

ID=27487067

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/001318 Ceased WO2002056908A2 (fr) 2001-01-16 2002-01-16 Cellules de presentation d'antigene

Country Status (1)

Country Link
WO (1) WO2002056908A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867283B2 (en) 2001-05-16 2005-03-15 Technion Research & Development Foundation Ltd. Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
JP2015500296A (ja) * 2011-12-09 2015-01-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 定義された動的形状を有する人工抗原提示細胞

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011702A1 (fr) * 1993-10-25 1995-05-04 Anergen, Inc. Expression procaryote de proteines du cmh
WO1997046256A1 (fr) * 1996-05-23 1997-12-11 The Scripps Research Institute Systemes de presentation d'antigenes de la classe ii du cmh et procedes d'activation des lymphocytes t a cd4?+¿
WO2000023053A2 (fr) * 1998-10-20 2000-04-27 Salvatore Albani Procede d'isolement, de quantification, de caracterisation et de modulation de cellules specifiques d'antigenes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011702A1 (fr) * 1993-10-25 1995-05-04 Anergen, Inc. Expression procaryote de proteines du cmh
WO1997046256A1 (fr) * 1996-05-23 1997-12-11 The Scripps Research Institute Systemes de presentation d'antigenes de la classe ii du cmh et procedes d'activation des lymphocytes t a cd4?+¿
WO2000023053A2 (fr) * 1998-10-20 2000-04-27 Salvatore Albani Procede d'isolement, de quantification, de caracterisation et de modulation de cellules specifiques d'antigenes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HILDEBRAND W ET AL: "Production and application of individual HLA proteins.", HUMAN IMMUNOLOGY, vol. 61, no. Supplement 2, 2000, 26th Annual Meeting of the American Society for Histocompatibility and Immunogenetics;Lake Buena Vista, Florida, USA; October 10-14, 2000, pages S81, XP008007733, ISSN: 0198-8859 *
JIANG WEIDONG ET AL: "Peptide/MHC monomers can be inserted into artificial lipid bilayers as artificial antigen presentation constructs.", BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), 43rd Annual Meeting of the American Society of Hematology, Part 1;Orlando, Florida, USA; December 07-11, 2001, November 16, 2001, pages 509a, XP001074308, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2002056908A2 (fr) 2002-07-25

Similar Documents

Publication Publication Date Title
EP2278022A3 (fr) Vecteurs d'expression, systèmes de transfection et procédé d'utilisation correspondant
WO2003049783A3 (fr) Dispositif et procedes pour recueillir des echantillons de tissus de geometrie connue
AU7478394A (en) Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
WO2003045427A3 (fr) Composition pharmaceutique servant a induire une reponse immune chez l'homme ou chez l'animal
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU2001256020A1 (en) Biological sounds monitor
WO2004093808A3 (fr) Nouveaux antigenes associes a une tumeur
WO2004084838A3 (fr) Identification, quantification, and caracterisation de lymphocytes t et d'antigenes ly
AU4423799A (en) Methods and agents for modulating the immune response and inflammation involvingmonocyte and dendritic cell membrane proteins
WO2001074855A3 (fr) Cellule dendritique compositions et methodes pour immunotherapie a base de cellules dendritiques
WO2000009677A3 (fr) Protease de site 1 regulee par des sterols et dosages de ses modulateurs
AU6930200A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
WO2002056908A3 (fr) Cellules de presentation d'antigene
WO2003051927A3 (fr) Production efficace de fragments f(ab')2 dans des cellules de mammiferes
EP1054487A3 (fr) Banc optique léger intégré et émetteur laser miniaturisé l'utilisant
AU2002212049A1 (en) Novel silicone material, its preparation method and the use thereof
AU1457199A (en) Isolation, characterization, and identification of dendritic like cells and methods of using same
WO2004058186A3 (fr) Formulations pour administration pulmonaire
AUPP729998A0 (en) Cryopreservation of porcine embryos and methods for producing piglets involving the same
AU2001273950A1 (en) Antibodies against native gp96, production and use thereof
WO2000004918A3 (fr) Agents utilises en immunotherapie d'affections tumorales
AU1657501A (en) Determining the functions and interactions of proteins by comparative analysis
AU7009600A (en) Method for obtaining dendritic cells, resulting dendritic cells and uses thereof for clinical purposes
WO2002074921A3 (fr) Methodes d'isolement de proteines exprimees au moyen de cellules dendritiques
AU2001245838A1 (en) Soluble mast cell function associated antigen (mafa) pharmaceutical compositionsand methods of making and using them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP